

## Bibliographie – Equipe V. Vieillard (2019)

2019

Boyd A, Boccara F, Meynard JL, Ichou F, Bastard JP, Fellahi S, **Samri A**, Sauce D, Haddour N, **Autran B**, Cohen A, Girard PM, Capeau J; Collaboration in HIV, Inflammation and Cardiovascular Disease study. Serum Tryptophan-Derived Quinolinate and Indole-3-Acetate Are Associated With Carotid Intima-Media Thickness and its Evolution in HIV-Infected Treated Adults. *Open Forum Infect Dis*. 2019 Dec 6;6(12):ofz516.

**Autran B**. [Alterations in responses to vaccines in older people]. *Rev Mal Respir*. 2019 Nov;36(9):1047-1056.

Rozencwajg S, **Guihot A**, Franchineau G, Lescroat M, Bréchet N, Hékimian G, Lebreton G, **Autran B**, Luyt CE, Combes A, Schmidt M. Ultra-Protective Ventilation Reduces Biotrauma in Patients on Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. *Crit Care Med*. 2019 Nov;47(11):1505-1512.

**Nakid-Cordero C**, Arzouk N, Gauthier N, **Tarantino N**, Larsen M, **Choquet S**, Burrel S, **Autran B**, **Vieillard V**, **Guihot A**. Skewed T cell responses to Epstein-Barr virus in long-term asymptomatic kidney transplant recipients. *PLoS One*. 2019 Oct 22;14(10):e0224211.

Bonnet B, Blum L, Charpentier C, Martres P, Ritvo PG, **Autran B**, **Guihot A**. Short Communication: Extremely Severe CD4 Lymphopenia During HIV-1 Primary Infection. *AIDS Res Hum Retroviruses*. 2019 Oct;35(10):930-933.

Combadière B, Beaujean M, Chaudesaigues C, **Vieillard V**. Peptide-Based Vaccination for Antibody Responses Against HIV. *Vaccines (Basel)*. 2019 Sep 2;7(3):105.

**Maucourant C**, Queiroz GAN, **Samri A**, Grassi MFR, Yssel H, **Vieillard V**. Zika virus in the eye of the cytokine storm. *Eur Cytokine Netw*. 2019 Sep 1;30(3):74-81.

**Hervier B**, Russick J, Cremer I, **Vieillard V**. NK Cells in the Human Lungs. *Front Immunol*. 2019 Jun 4;10:1263.

HIV therapeutic vaccine enhances non-exhausted CD4<sup>+</sup> T cells in a randomised phase 2 trial. **Vieillard V**, Combadière B, Tubiana R, Launay O, Pialoux G, Cotte L, Girard PM, Simon A, Dudoit Y, Reynes J, Rockstroh J, Garcia F, Gatell J, Devidas A, Yazdanpanah Y, Weiss L, Fätkenheuer G, **Autran B**, Joyeux D, Gharakhanian S, **Debré P**, Katlama C. *NPJ Vaccines*. 2019 Jun 3;4:25.

Shiina T, Suzuki S, Congy-Jolivet N, Aarnink A, Garchon HJ, Dereuddre-Bosquet N, Vaslin B, Tchitchek N, Desjardins D, **Autran B**, Lambotte O, Theodorou I, Le Grand R, Blancher A. Cynomolgus macaque IL37 polymorphism and control of SIV infection. *Sci Rep*. 2019 May 28;9(1):7981.

Queiroz GAN, Mascarenhas REM, **Vieillard V**, Andrade RL, Galvão-Castro B, Grassi MFR. Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. *BMC Infect Dis*. 2019 May 17;19(1):433.

**Samri A**, Charpentier C, **Diallo MS**, Bertine M, Even S, **Morin V**, **Oudin A**, Parizot C, Collin G, Hosmalin A, Cheynier R, Thiébaud R, Matheron S, Collin F, Zoorob R, Brun-Vézinet F, **Autran B**; ANRS CO5 IMMUNOVIR-2 Study Group. Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection. *PLoS Pathog*. 2019 May 16;15(5):e1007758.

Bennabi M, **Tarantino N**, Gaman A, Scheid I, Krishnamoorthy R, **Debré P**, Bouleau A, Caralp M, Gueguen S, Le-Moal ML, Bouvard M, Amestoy A, Delorme R, Leboyer M, Tamouza R, **Vieillard V**. Persistence of dysfunctional natural killer cells in adults with high-functioning autism spectrum disorders: stigma/consequence of unresolved early infectious events? *Mol Autism*. 2019 May 15;10:22.

Dorgham K, Pietrancosta N, Affoune A, **Lucar O**, Bouceba T, Chardonnet S, Pionneau C, Piesse C, Sterlin D, Guardado-Calvo P, Karoyan P, **Debré P**, Gorochov G, **Vieillard V**. Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope. *J Immunol Res*. 2019 Mar 24;2019:9804584.

Xu J, Merlier F, Avalle B, **Vieillard V**, **Debré P**, Haupt K, Tse Sum Bui B. Molecularly Imprinted Polymer Nanoparticles as Potential Synthetic Antibodies for Immunoprotection against HIV. *ACS Appl Mater Interfaces*. 2019 Mar 13;11(10):9824-9831.

**Wauquier N**, **Petitdemange C**, **Tarantino N**, **Maucourant C**, Coomber M, Lungay V, Bangura J, **Debré P**, **Vieillard V**. HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2<sup>+</sup> NK cells in Lassa virus infection. *EBioMedicine*. 2019 Feb;40:605-613.

**Maucourant C**, **Petitdemange C**, Yssel H, **Vieillard V**. Control of Acute Arboviral Infection by Natural Killer Cells. *Viruses*. 2019 Jan 31;11(2):131.

**Lucar O**, **Sadjo Diallo M**, Bayard C, **Samri A**, **Tarantino N**, **Debré P**, Thiébaud R, Brun-Vézinet F, Matheron S, Cheynier R, **Vieillard V**; ANRS CO5 IMMUNOVIR-2 Study group. B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape. *AIDS*. 2019 Jan 27;33(1):23-32.

Avettand-Fenoel V, Bayan T, Gardiennet E, Boufassa F, Lopez P, Lecuroux C, Noel N, Trémeaux P, Monceaux V, **Autran B**, Meyer L, Saez-Cirion A, Lambotte O, Rouzioux C; CODEX ANRS Cohort Study Group. Dynamics in HIV-DNA levels over time in HIV controllers. *J Int AIDS Soc*. 2019 Jan;22(1):e25221.